Valirx Plc Collaboration Agreement Signed

The new U.S. sales offices will play an important role in connecting and reflecting clients in Boston and San Diego, both of which are central locations for the pharmaceutical industry in the United States. The new service contract with Regus provides Pharmatest with an excellent opportunity to contact and serve customers at multiple locations in the U.S. and around the world. Valirx CEO Satu Vainikka said: “Valirx is pleased to conclude this three-year contract with Pharmatest. The work that Pharmatest has done in recent years for Valirx in our other programs has been of very high quality, and we are confident that this agreement will significantly accelerate the development of the GeneICE project. This additional use for VAL201, which is the subject of collaborative analysis, has no impact on ValiRx`s intellectual property rights, nor on the progress or commercial potential of oncology or endometriosis applications used for VAL201 or VAL301. – VAL401 reduces the volume of the tumor in a Xenograft model of pancreatic cancer using a new improved luciferase identification technique (in collaboration with Valirx Plc) Turkish company Pharmatest Services Ltd (Pharmatest) has signed a Master Service Agreement with London-listed valirx plc (Valirx). The agreement makes Pharmatest a preferred supplier of preclinical efficacy tests for Valirx in its cancer drug development programs. Pharmatest Services Ltd (Pharmatest) has been the preferred supplier of Bayer Pharma AG (Bayer) since 2010. The results of several projects at Pharmatest regarding the new FDA-approved cancer drug Xofigo were released last week, and Bayer said it was impressed with the high quality work done by Pharmatest during the collaboration. Transgene S.A. is a long-term French client that enjoys the organisational status of Pharmatest`s research and development.

Transgene welcomed the long-standing collaboration with Pharmatest and recently explained this in a public testimony. London, Ukde , June 2, 2020: ValiRx (AIM:VAL) announces that it has entered into a cooperation agreement with Oncolytika Limited (“Oncolytika”) and Black Cat Limited (“Black Cat”) to investigate the use of VAL201 in a combined treatment for patients with a hyperimmunizing response to SARS CoV2 coronavirus infection (the “project”). Dr. Suzanne Dilly is nominated as Chair of the Project Steering Committee. As announced on May 1, 2020, the company intends to appoint Dr. Suzanne Dilly to lead the company, subject to the conclusion of satisfactory substantive reviews currently underway.